T
Tome Biosciences
Tome Biosciences is the programmable gene insertion company
About Tome Biosciences
Tome Biosciences operates in the biotechnology sector, specializing in programmable gene insertion technologies. Utilizing CRISPR, a powerful tool for editing genomes, the company can insert any genetic sequence of any size at any location within any genome. This capability positions Tome Biosciences at the forefront of genomic medicine, aiming to deliver precise cures to patients through advanced cell and genome engineering.
The company primarily serves the healthcare and pharmaceutical industries, targeting clients such as research institutions, hospitals, and biotech firms. Tome Biosciences' business model revolves around developing and licensing its proprietary gene-editing technologies, as well as forming strategic partnerships with other entities in the biotech and pharmaceutical sectors.
Revenue is generated through a combination of licensing fees, research and development collaborations, and potentially, future sales of gene-editing therapies. The company is based in Cambridge, MA, and is actively recruiting talent to further its mission of revolutionizing genomic medicine.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Watertown, United States
- Employees
- 137
- Open positions
- None listed
- Dealroom signal
- 30.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2023 | $128M | $512M | GV · Polaris Partners · Longwood Fund · Alexandria Venture Investments | ↗ |
| SERIES AOther financing | Dec 2022 | $85M | $340M | GV · Polaris Partners · Longwood Fund · ARCH Venture Partners | ↗ |
Growth signals
Latest recorded traffic for Tome Biosciences is 780 monthly website visits, down 15.2% over the last three months. Tome Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Andreessen Horowitz
Polaris Partners
Longwood Fund
ARCH Venture Partners
GV
Bruker
FUJIFILM
Alexandria Venture Investments
Other known investors1 additional known investor
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tome Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tome Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.